The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

The unidentified 26-year-old man fell to his death while creating social media content, according to local authorities. A new study shines light on a hotly contested centuries-old mystery. Lamine ...

The group is alleged to have made fake labels from famous French vineyards, using them to sell cheap wine. The formidable Italian player made it to Wimbledon three times, turning heads with every ...

LUMAKRAS, and the newly launched IMDELLTRA. The rare diseases segment also did well. This segment enjoyed a bigger focus after Amgen acquired Horizon Therapeutics. In 2Q24, it achieved more than $ ...

Kamala Harris is depicted on NBC News accepting the Democratic presidential nomination. Screenshot: Press Gazette Most of the world’s most-visited English-language news sites grew traffic year ...

A severe solar storm is headed to Earth that could stress power grids even more as the US deals with disruptions from Hurricane Milton that hit Florida .

Some of its most recent brand-new launches, especially the cancer drug Lumakras, have made paltry (at best) contributions to its top line, while some of its legacy products are racking up ...

NEW YORK – The first data from a trial of Amgen's KRAS inhibitor Lumakras (sotorasib) combined with its anti-EGFR monoclonal antibody Vectibix (panitumumab) and chemo in first-line KRAS G12C-mutant ...